Information on the decisions of foreign regulatory authorities

Information on the decisions of foreign regulatory authorities

Show other versions (2)

При анализе рекомендаций российских и зарубежных регуляторных органов об ограничении обращения лекарственных средств и/или о необходимости внесения изменений в инструкции по их медицинскому применению в связи с изменением оценки профиля безопасности, сотрудниками ЦЭБЛС ФГБУ «НЦЭСМП» Минздрава России...

Full description

Bibliographic Details
Main Authors:	T. M. Bukatina, E. Yu. Pasternak, B. K. Romanov, R. N. Alyautdin, V. K. Lepakhin, A. S. Kazakov, K. E. Zatolochina, I. I. Snegireva, M. A. Darmostukova, E. Yu. Kolesnikova, E. O. Zhuravleva, T. V. Romanova, N. Yu. Velts, M. L. Maksimov, G. V. Kutekhova
Format:	Article
Language:	Russian
Published:	Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products» of the Ministry of Health of the Russian Federation 2018-02-01
Series:	Безопасность и риск фармакотерапии
Online Access:	https://www.risksafety.ru/jour/article/view/60

Similar Items

Information on the decisions of foreign regulatory authorities
by: T. M. Bukatina, et al.
Published: (2018-02-01)

Information on the decisions of foreign regulatory authorities
by: T. M. Bukatina, et al.
Published: (2018-02-01)

Analysis of the decisions of foreign regulatory authorities
by: T. M. Bukatina, et al.
Published: (2018-02-01)

Analysis of the decisions of foreign regulatory authorities
by: T. M. Bukatina, et al.
Published: (2018-02-01)

Foreign regulatory recommendations
by: T. M. Bukatina, et al.
Published: (2018-02-01)

MYOPATHY CAUSED BY THE INTERACTION OF COLCHICINE AND STATINS
by: A. S. Kazakov, et al.
Published: (2018-09-01)

The risk of an acute attack of angle-closure glaucoma during the treatment with modern antidepressant drugs
by: T. V. Romanova, et al.
Published: (2018-02-01)

Modern approaches to collecting and reporting information on side effects
by: K. E. Zatolochina, et al.
Published: (2018-02-01)

UNEXPECTED ADVERSE REACTIONS OF THE DRUGS OF THE GROUP OF INHIBITORS OF DIPEPTIDYL PEPTIDASE-4
by: T. V. Romanova, et al.
Published: (2018-06-01)

Inhibitors of sodium-glucose cotransporter 2: risk of ketoacidosis
by: T. M. Bukatina, et al.
Published: (2018-02-01)

Ketoacidosis as unexpected adverse reaction SGLT<sub>2</sub> inhibitor
by: T. M. Bukatina, et al.
Published: (2018-02-01)

On improving the safety of new direct acting oral anticoagulants
by: N. Yu. Velts, et al.
Published: (2018-02-01)

Signal Messages in Pediatric Practice
by: G. V. Kutekhova, et al.
Published: (2018-12-01)

Analysis of spontaneous reports of adverse reactions, developed in the use of drugs during pregnancy
by: E. O. Zhuravleva, et al.
Published: (2018-02-01)

POST-MARKETING DRUG SAFETY RESEARCH: ANALYSIS OF RECOMMENDATIONS OF FOREIGN REGULATORS
by: E. V. Shubnikova, et al.
Published: (2018-09-01)

Safety of apremilast: risk of psychical disorders
by: T. M. Bukatina, et al.
Published: (2018-02-01)

The risk management system as the important part of good pharmacovigilance practices (GVP)
by: A. S. Kazakov, et al.
Published: (2018-02-01)

On the interchangeability of calcineurine inhibitors
by: K. E. Zatolochina, et al.
Published: (2018-02-01)

SIGNAL AS A TOOL OF THE PHARMACOVIGILANCE
by: E. O. Zhuravleva, et al.
Published: (2018-06-01)

Statistical signal detection methods
by: K. E. Zatolochina, et al.
Published: (2018-02-01)

Nonsteroidal anti-inflammatory drugs: problems of safe use
by: N. Yu. Velts, et al.
Published: (2018-03-01)

The Adverse Drug Reactions Registered During the Postmarketing Period
by: E. V. Shubnikova, et al.
Published: (2019-03-01)

Problems of interchangeability of systemic interferons for treatment of multiple sclerosis
by: I. I. Snegireva, et al.
Published: (2018-02-01)

International Drug Safety Monitoring
by: A. S. Kazakov, et al.
Published: (2019-09-01)

Social media as a source of information on drug safety and how to extract it
by: I. I. Snegireva, et al.
Published: (2018-02-01)

Modern approaches to vaccines interchangeability
by: I. I. Snegireva, et al.
Published: (2018-02-01)

Interferon Beta: Analysis of Information on Adverse Reactions and Evaluation of Possibility of Signal Identification
by: K. E. Zatolochina, et al.
Published: (2019-06-01)

Comparative Analysis of International Databases of Adverse Drug Reactions
by: A. S. Kazakov, et al.
Published: (2020-09-01)

The rules of good laboratory practice
by: N. Yu. Velts, et al.
Published: (2018-02-01)

Malaria and safety issues associated with antimalarial drugs
by: A. S. Kazakov, et al.
Published: (2018-02-01)

Vaccine Safety International Monitoring
by: M. A. Darmostukova, et al.
Published: (2019-03-01)

Nicotine dependence and neuropsychotic effects of varenicline
by: T. M. Bukatina, et al.
Published: (2018-03-01)

ON THE ISSUE OF SAFETY OF NON-STEROIDAL ANTI-INFLAMMATORY DRUGS
by: N. Yu. Velts, et al.
Published: (2018-09-01)

Nanoscale Therapeutic System: Safety Assessment Features
by: E. M. Bovina, et al.
Published: (2019-09-01)

Rules of good laboratory practice: analysis of changes in the legislation
by: N. Yu. Velts, et al.
Published: (2018-02-01)

Drug-induced liver injuries in pregnancy in the context of polypragmasy
by: N. Yu. Velts, et al.
Published: (2018-02-01)

Practical recommendations for screening of information on the drug safety
by: E. Yu. Pasternak, et al.
Published: (2018-02-01)

Monitoring Drug Safety Information - Recommendations of Foreign Regulatory Authorities
by: Elena V. Shubnikova, et al.
Published: (2020-03-01)

The risk of milk thistle (<i>Silybum marianum</i>) drug interactions
by: A. S. Kazakov, et al.
Published: (2018-02-01)

Expert Evaluation of Pharmacovigilance System Documents Included in the Registration Dossier
by: I. I. Snegireva, et al.
Published: (2020-12-01)